Adicet Bio's ADI-001 Receives Fast Track Designation for Lupus Therapy Development

Adicet Bio Secures Fast Track Designation for Groundbreaking Therapy ADI-001

Adicet Bio, Inc. announces a significant milestone in its development of innovative therapies for autoimmune diseases and cancer, as the U.S. Food and Drug Administration (FDA) grants Fast Track Designation to its investigational therapy ADI-001. This designation is specifically for the treatment of adult patients suffering from refractory systemic lupus erythematosus (SLE) with extrarenal involvement. ADI-001 represents a novel approach in the realm of allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies, targeting CD20 to address the complexities of autoimmune conditions. Previously, Adicet has also received Fast Track Designation for ADI-001 in treating relapsed/refractory class III or class IV lupus nephritis (LN), underscoring the therapy’s potential in addressing critical therapeutic gaps in lupus management.

The company’s commitment to advancing ADI-001 is evidenced by its ongoing Phase 1 study for lupus nephritis, with patient enrollment currently underway. Looking ahead, Adicet plans to initiate enrollment for SLE, systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), and stiff person syndrome (SPS) in the first quarter of 2025. Furthermore, plans to begin enrollment for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) are anticipated for the latter half of 2025. This robust pipeline highlights Adicet's strategic focus on multiple autoimmune indications, showcasing the versatility of ADI-001 and its potential to provide meaningful relief to patients enduring these challenging conditions.

In earlier studies, ADI-001 has demonstrated promising results in effectively targeting B-cells through the anti-CD20 CAR, achieving substantial CD19+ B-cell depletion in both peripheral blood and secondary lymphoid tissues. This capability is crucial in the management of autoimmune diseases, where B-cell activity often exacerbates disease pathology. Adicet Bio is dedicated to developing "off-the-shelf" gamma delta T cell therapies that not only prioritize accessibility but also aim for durable therapeutic outcomes in patients. The Fast Track Designation serves as a notable endorsement from the FDA, potentially accelerating the development and availability of ADI-001 for patients in need.

As Adicet Bio continues to navigate its clinical trials and expand its therapy indications, the focus remains on addressing significant unmet medical needs within the autoimmune disease landscape. The company’s innovative approach to T cell therapy exemplifies the strides being made in biotechnology, particularly in the development of targeted treatments that aim to improve patient outcomes in complex diseases like lupus. For more information about Adicet Bio and its advancements, interested parties can visit their website at https://www.adicetbio.com.